PROGNOSTIC SIGNIFICANCE OF SOME MARKERS OF ENDOTHELIAL DYSFUNCTION IN THE DEVELOPMENT OF CHRONIC KIDNEY PATHOLOGY IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE
https://doi.org/10.24884/1561-6274-2018-22-5-25-30
Abstract
Currently, accumulated a large amount of data on the role of inflammation in the vascular endothelium damage during the development of the chronic forms of many diseases. THE AIM: identification of endothelial dysfunction (ED) biomarkers as early predictors of CKD development in patients with chronic lung diseases. PATIENTS AND METHODS. 123 patients with COPD aged 55-79 years were examined, studied features of clinical and anthropometric parameters, data of the main biochemical systemic inflammation markers and vascular endothelial dysfunction, their significance in the development of chronic kidney disease (CKD). RESULTS. For the first time CKD was diagnosed in 51.2% of patients with COPD. In comorbid patients with COPD and related CKD noted more severe course of disease. Also in these patients detected significantly elevated endothelial dysfunction indices. CRP and fibrinogen levels were higher in all patients with COPD and authentically correlated with disease severety. Direct correlation between CRP and TNF-α levels was revealed. Noted that tumor necrosis factor was higher in smoker patients with COPD. Markers of kidneys endothelial dysfunction – homocysteine, IL-6, IL-8 – were significantly higher in patients with decreased GFR. Also in these patients were detected increased levels of serum creatinine and urea. Creatinine clearance inversely correlated with homocysteine plasma level. In all cases of fibrinogen increase in patients with COPD. Homocysteine level was also increased, but in combination with CKD it was significantly higher: respectively 19,8±7,51 and 39,8 ± 7,14 μmol/L, p<0,005. CONCLUSION. The received information confirms the hypothesis about the relationship of ED biomarkers homocysteine, TNF-α, IL-6, IL-8 with the development of chronic kidney disease in comorbid patients with COPD.
About the Authors
N. V. AgranovichRussian Federation
Department of Polyclinic Therapy
355017, Russia, Stavropol, str. Mira, 310, Stavropol
Prof. Nadezhda V. Agranovich, MD, PhD, DMedSci
Phone: 8(962)443-04-50
L. A. Pilipovich
Russian Federation
Department of Polyclinic Therapy
355017, Russia, Stavropol, str. Mira, 310, Stavropol
MD, assistant
Phone. 8 9034466988
L. V. Albotova
Russian Federation
Department of Polyclinic Therapy
355017, Russia, Stavropol, str. Mira, 310, Stavropol
Graduate student
Phone: 8(928)365-55-56
References
1. Зыков КА, Соколов ЕИ. Новая классификация хронической обструктивной болезни лёгких: новые возможности или новые проблемы? Consillium Medicum 2013; (5): 42–47 [Zykov KA, Sokolov EI. A new classification of chronic obstructive pulmonary disease: new opportunities or new problems? Consillium Medicum 2013; (5): 42-47]
2. Global Initiative for Chronic Obstructive Lung Disease (GOLD, пересмотр 2016). Режим доступа:http://www.goldcopd.org (Global Initiative for Chronic Obstructive Lung Disease (GOLD, 2016). Available at: http://www.goldcopd.org)
3. Кузьмицкая ЮС, Пырочкин ВМ. Биохимические маркеры воспаления. Медицинские новости 2010; (7): 22–27 [Kuzmitskaya YuS, Pyrochkin VM. Biochemical markers of inflammation. Medical News 2010; (7): 22-27]
4. Лещенко ИВ, Баранова ИИ. Биомаркеры воспаления при хронической обструктивной болезни легких. Пульмонология 2012; (2): 108-117 DOI: 10.18093/0869- 0189-2012-0-2-108-117 [Leschenko I.V., Baranova I.I. Biomarkers of inflammation in chronic obstructive pulmonary disease. Pulmonology 2012; (2): 108-117. DOI: 10.18093/0869-0189- 2012-0-2-108-117].
5. Brunekreef B, Holgate ST. Air pollution and health. Lancet 2002; 360: 1233–1242
6. Schlesinger RB, Kunzli N, Hidy GM et al. The health relevance of ambient particulate matter characteristics: coherence of toxicological and epidemiological inferences. Inhal Toxicol 2006; 18: 95–125
7. Агранович НВ, Пилипович ЛА, Мацукатова ВС и др. Маркеры ранних проявлений почечной эндотелиальной дисфункции у пожилых пациентов ХОБЛ. Кардиоваскулярная терапия и профилактика 2017. Дополнительный выпуск: 5-6 [Agranovich NV, Pilipovich LA, Matsukatova VS and others. Markers of early manifestations of renal endothelial dysfunction in elderly COPD patients. Cardiovascular therapy and prevention 2017. Additional issue: 5-6]
8. Фатеева ВВ, Воробьева ОВ. Маркеры эндотелиальной дисфункции при хронической ишемии мозга. Журнал неврологии и психиатрии им. С.С. Корсакова 2017; 117 (4): 107- 112. DOI: 10.17116/jnevro201711741107-111 [Fateeva VV, Vorobyova OV. Markers of endothelial dysfunction in chronic cerebral ischemia. Journal of Neurology and Psychiatry. S.S. Korsakov. 2017: 117 (4):107-112. DOI: 10.17116/jnevro201711741107-111].
9. Шевченко ОП, Долгов ВВ, Гичкун ОЕ и др. Гомоцистеин при трансплантации печени детям раннего возраста. Вестник трансплантологии и искусственных органов 2012; 14(4): 44-47. DOI: 10.15825/1995-1191-2012-4-44-47. [Shevchenko OP, Dolgov VV, Gichkun OE. Homocysteine for liver transplantation for infants. Herald of transplantology and artificial organs. 2012; 14 (4): 44-47. DOI: 10.15825/1995-1191-2012-4-44-47.]
10. Батюшин ММ, Гадаборшева ХЗ, Сарвилина ИВ и др. Взаимосвязь MCP-1 и тубулоинтерстициального фиброза при хроническом гломерулонефрите. Нефрология 2017;21(5):22- 27. DOI: 10.24884/1561-6274-2017-21-5-19-24 [Batiushin MM, Gadaborsheva HZ, Sarvilina IV et al. The relationship of MCP-1 and tubulointerstitial fibrosis in chronic glomerulonephritis. Nephrology (Saint-Petersburg). 2017;21(5):22-27 (In Russ.). DOI: 10.24884/1561-6274-2017-21-5-19-24]
11. Батюшин ММ, Гадаборшева ХЗ. Белок сосудистой адгезии-1 (VAP-1) и его роль в моделировании воспалительного процесса и фиброза. Нефрологический вектор. Нефрология 2015;19(5):23-27 [Batiushin MM, Gadaborsheva HZ. Vascular adhesive protein- 1 (VAP-1) and its role in modeling of inflammation and fibrosis. Nephrology vector. Nephrology (Saint-Petersburg). 2015;19(5):23-27 (In Russ.).]
12. Уразаева ЛИ, Максудова АН. Биомаркеры раннего повреждения почек: Нефрология, практическая медицина, инновационные технологии в медицине. Редактор 2014: (1): 125- 130 [Urazaeva LI, Maksudova AN. Biomarkers of early kidney damage: Nephrology, practical medicine, innovative technologies in medicine. Editor 2014; (1): 125-130]
13. Агранович НВ, Пустовей ДВ, Алботова ЛВ. Анализ взаимосвязи развития хронической болезни почек у пациентов старших возрастных групп с сердечно- сосудистой патологией. Задачи амбулаторного звена в ранней диагностике и профилактике. Современные проблемы науки и образования 2015; (5): URL: www.science-education.ru/128-22649 [Agranovich NV, Pustovay DV, Albotova LV Analysis of the relationship between the development of chronic kidney disease in patients of older age groups with cardiovascular pathology. Outpatient tasks in early diagnosis and prevention. Modern problems of science and education 2015; (5) URL: www.science- education.ru/128-22649]
14. Будневский АВ, Овсянников ЕС, Чернов АВ и др. Биомаркеры как предикторы исходов хронической обструктивной болезни легких (обзор литературы). Молодой ученый 2014; (5): 125-128 [Budnevsky AV, Ovsyannikov ES, Chernov AV et al. Biomarkers as predictors of outcomes of chronic obstructive pulmonary disease (literature review). The young scientist. 2014; (5): 125-128]
15. Будневский АВ, Овсянников ЕС, Чернов АВ и др. Диагностическое значение биомаркеров системного воспаления при хронической обструктивной болезни легких. Клиническая медицина 2014; (9): 16-21 [Budnevsky AV, Ovsyannikov ES, Chernov AV et al. Diagnostic value of biomarkers of systemic inflammation in chronic obstructive pulmonary disease. Clinical medicine. 2014; (9): 16-21]
16. Rosenberg SR, Kalhan R. Biomarkers in chronic obstructive pulmonary disease. Transl es 2012; 159: 28-37
17. Гусина АА. Гипергомоцистеинемия: причины и механизмы повреждающего действия. Весцi Нац Акад навук Беларусi 2007; (2): 117–123 [Gusina AA. Hyperhomocysteinemia: causes and mechanisms of damaging action Vesci Nat. Acad. the Belarusian. 2007; (2): 117-123]
18. Сидоренко ГИ, Майсеенок АГ, Колядко МГ и др. Роль гомоцистеина в тромбо- и атерогенезе. Возможности и перспективы витаминной коррекции. Кардиология 2001; (3): 56–61 [Sidorenko, GI, Maysenok AG, Kolyadko MG et al. The role of homocysteine in thrombotic and atherogenesis. Opportunities and prospects of vitamin correction. Cardiology 2001; (3): 56-61]
19. Daly S, Cotter A, Molloy AE. Homocysteine and folic acid: implications for pregnancy. Semin Vasc Med 2005; 5 (2):190-200. DOI: 10.1055/s-2005-872404
20. Костюченко ГИ, Баркаган ЗС. Гипергомоцистеинемия и коронарная болезнь сердца как проблема пожилого возраста. Клин геронтология 2003; 9 (5): 9–12 [Kostyuchenko GI, Barkagan ZS. Hyperhomocysteinemia and coronary heart disease as a problem of the elderly. Wedge. gerontology 2003; 9 (5): 9-12]
Review
For citations:
Agranovich N.V., Pilipovich L.A., Albotova L.V. PROGNOSTIC SIGNIFICANCE OF SOME MARKERS OF ENDOTHELIAL DYSFUNCTION IN THE DEVELOPMENT OF CHRONIC KIDNEY PATHOLOGY IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE. Nephrology (Saint-Petersburg). 2018;22(5):25-30. (In Russ.) https://doi.org/10.24884/1561-6274-2018-22-5-25-30